G1 Therapeutics to Release Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update on March 1, 2023
G1 Therapeutics (Nasdaq: GTHX) will hold a webcast and conference call on March 1, 2023, at 8:30 a.m. ET to discuss its corporate and financial results for Q4 and the full year of 2022. This marks an important update for investors. Participants can register for the call and access a live and archived webcast on the company's website, which will be available for 90 days post-event. G1 Therapeutics focuses on next-generation therapies for cancer, including its product COSELA (trilaciclib), and has an ongoing tumor-agnostic clinical development plan targeting various solid tumors.
- G1 Therapeutics is set to provide a corporate and financial update, potentially indicating growth or stability.
- The company is focused on COSELA, targeting a broad range of cancers, which could enhance market position.
- None.
RESEARCH TRIANGLE PARK, N.C., Feb. 22, 2023 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, will host a webcast and conference call to provide a corporate and financial update for the fourth quarter and full year 2022 on Wednesday, March 1, 2023, at 8:30 a.m. ET.
Please note that there is a new process to access the call via telephone. To register and receive a dial in number and unique PIN to access the live conference call, please follow this link to register online. While not required, it is recommended that you join 10 minutes prior to the start of the event. A live and archived webcast will be available on the Events & Presentations page of the company’s website: www.g1therapeutics.com. The webcast will be archived on the same page for 90 days following the event.
About G1 Therapeutics
G1 Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of next generation therapies that improve the lives of those affected by cancer, including the Company’s first commercial product, COSELA® (trilaciclib). G1 has a deep clinical pipeline and is executing a tumor-agnostic development plan evaluating COSELA in a variety of solid tumors, including breast, lung, and bladder cancers. G1 Therapeutics is based in Research Triangle Park, N.C. For additional information, please visit www.g1therapeutics.com and follow us on Twitter @G1Therapeutics.
G1 Therapeutics® and the G1 Therapeutics logo and COSELA® and the COSELA logo are trademarks of G1 Therapeutics, Inc.
G1 Therapeutics Contacts:
Will Roberts
Vice President
Investor Relations and Corporate Communications
(919) 907-1944
wroberts@g1therapeutics.com
Rebecca Levine
Director, Corporate Communications and Public Relations
(919) 667-8711
rlevine@g1therapeutics.com
FAQ
What is G1 Therapeutics' upcoming event on March 1, 2023?
How can I access the G1 Therapeutics conference call?
What is G1 Therapeutics' primary product?
Where can I find the archived webcast of G1 Therapeutics' event?
